Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure10' education - Oct. 12, 2022 - Clara Bonanad Lozano, MD, PhD - Valencia, Spain
Video navigation menu
- 2022 AHA/ACC/HFSA guideline for the management of heart failure 00:55
- Reasons that justify the need to optimize treatments in HF despite the risk of hyperkalemia 02:01
- Practical guidance on how to use novel potassium binders 03:37
- Conclusions 08:11
This lecture by Clara Bonanad Lozano was part of the EBAC-accredited symposium "Clinical Case Discussion: The value of optimizing RAAS inhibition and preserving normokalemia in heart failure" held during the ESC congress 2022.
Clara Bonanad is Clinical Cardiologist at the Hospitalization Unit of Cardiology, University Clinical Hospital of Valencia and clinical researcher at the Instituto de Salud Carlos III. She is Associate Professor at the Department of Medicine, Faculty of Medicine of the University of Valencia since 2019 and teaching assistant in Cardiology at the Faculty of Medicine of Valencia, since 2012.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from AstraZeneca.